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The response to respiratory viruses varies substantially between individuals, and there are
currently no known molecular predictors from the early stages of infection. Here we conduct a
community-based analysis to determine whether pre- or early post-exposure molecular factors
could predict physiologic responses to viral exposure. Using peripheral blood gene expression
proﬁles collected from healthy subjects prior to exposure to one of four respiratory viruses
(H1N1, H3N2, Rhinovirus, and RSV), as well as up to 24 h following exposure, we ﬁnd that it is
possible to construct models predictive of symptomatic response using proﬁles even prior to
viral exposure. Analysis of predictive gene features reveal little overlap among models; however,
in aggregate, these genes are enriched for common pathways. Heme metabolism, the most
signiﬁcantly enriched pathway, is associated with a higher risk of developing symptoms fol-
lowing viral exposure. This study demonstrates that pre-exposure molecular predictors can be
identiﬁed and improves our understanding of the mechanisms of response to respiratory viruses.
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Acute respiratory viral infections are among the most com-mon reasons for outpatient clinical encounters1. Symptomsof viral infection may range from mild (e.g. sneezing, runny
nose) to life-threatening (dehydration, seizures, death), though
many individuals exposed to respiratory viruses remain entirely
asymptomatic2. Variability in individuals’ responses to exposure has
been observed both in natural infections3 and controlled human
viral exposure studies. Speciﬁcally, some individuals remained
asymptomatic despite exposure to respiratory viruses, including
human rhinovirus (HRV)4–6, respiratory syncytial virus (RSV)4–6,
inﬂuenza H3N24–9, and inﬂuenza H1N14,5,9. Factors responsible
for mediating response to respiratory viral exposure are poorly
understood. These individual responses are likely inﬂuenced by
multiple processes, including the host genetics10, the basal state of
the host upon exposure11, and the dynamics of host immune
response in the early hours immediately following exposure and
throughout the infection12. Many of these processes occur in the
peripheral blood through activation and recruitment of circulating
immune cells13. However, it remains unknown whether host factors
conferring resilience or susceptibility to symptomatic infectious
disease can be detected in peripheral blood before infection, or
whether they are only apparent in response to pathogen exposure.
In order to identify such gene expression markers of resilience
and susceptibility to acute respiratory viral infection, we utilized
gene expression data from seven human viral exposure
experiments6,7,9. These exposure studies have shown that global
gene expression patterns measured in peripheral blood around the
time of symptom onset (as early as 36 h after viral exposure) are
highly correlated with symptomatic manifestations of illness6,9.
However, these later-stage observations do not necessarily reﬂect
the spectrum of early timepoint immune processes that might
predict eventual infection. Since transcriptomic signals are weak at
these early timepoints, the detection of early predictors of viral
response has not yet been possible in any individual study. By
combining data collected across these seven studies and leveraging
the community to implement state-of-the-art analytical algorithms,
the Respiratory Viral DREAM Challenge (www.synapse.org/
ViralChallenge) aims to develop early predictors of resilience or
susceptibility to symptomatic manifestation based on expression
proﬁles that are collected prior to and at early timepoints following
viral exposure and to understand the biological mechanisms
underlying those predictors.
Results
Human viral exposure experiments. In order to determine
whether viral susceptibility could be predicted prior to viral expo-
sure, we collated seven human viral exposure experiments: one
RSV, two inﬂuenza H1N1, two inﬂuenza H3N2, and two HRV
studies, in which a combined total of 148 healthy volunteers were
exposed to virus (Supplementary Data 1; Fig. 1a−c) or sham (n=
7)6,7,9. Subjects were excluded if pre-existing neutralizing antibodies
were detected, except for the RSV study in which neutralizing
antibodies were not an exclusion criteria. Each subject in the study
was followed for up to 12 days after exposure and serially sampled
for peripheral blood gene expression by Affymetrix Human U133A
2.0 GeneChips. Throughout the trial, subjects self-reported clinical
symptom scores across 8−10 symptoms (Supplementary Figure 1).
These data were used to stratify subjects as either symptomatic or
asymptomatic and to quantify symptom severity. Additionally,
nasopharyngeal swabs measured viral shedding; these data were
used to stratify subjects as either shedders or nonshedders (Fig. 1d).
Clinical symptoms were summarized based on a modiﬁed Jackson
score14 and viral shedding was determined to be present if two or
more measurable titers or one elevated titer was observed within 24
h following viral exposure15. Viral shedding and clinical symptoms
were provided to the Respiratory Viral DREAM Challenge parti-
cipating teams only for the training data set (Fig. 1b). An additional,
but not previously available, human exposure experiment to the
RSV virus (n= 21) was used as an independent test data set
(Fig. 1b, c). The study design for this data set was similar to those of
the seven original data sets.
Data analysis challenge. Using these data, an open data analysis
challenge, the Respiratory Viral DREAM Challenge, was for-
mulated. Teams were asked to predict viral shedding and clinical
symptoms based on peripheral blood gene expression data from
up to two timepoints: prior to viral exposure (T0) or up to 24 h
post viral exposure (T24). Based on gene expression data from the
two timepoints, teams were asked to predict at least one of three
outcomes: presence of viral shedding (subchallenge 1 (SC1)),
presence of symptoms, deﬁned as a modiﬁed Jackson score ≥ 6
(subchallenge 2 (SC2)), or symptom severity, deﬁned as the
logarithm of the modiﬁed Jackson score (subchallenge 3 (SC3)).
Teams were asked to submit predictions based on gene expression
and basic demographic (age and gender) data from both time-
points to enable cross-timepoint comparison. The seven collated
data sets served as a training data set on which teams could build
their predictive models. For a subset of subjects (n= 23), phe-
notypic data were withheld to serve as a leaderboard test set for
evaluation with real-time feedback to teams (Fig. 1a).
Teams were asked to submit at least one leaderboard submission
at each timepoint to be evaluated on the leaderboard test set.
Performance metrics for these models were returned in real time,
and teams could update their submissions accordingly up to a
maximum of six combined submissions per subchallenge. At the
end of this exercise, teams were asked to provide leave-one-out
cross-validation-based predictions on the training set (LOOCVs)
and predictor lists for each of their best models.
Each team’s best models (one for T0 and one for T24) per
subchallenge were ultimately assessed on the held-out human
RSV exposure data set that had not been publicly available,
previously (Fig. 1a). Predictions for the binary outcomes
(shedding and symptoms) were assessed using Area Under the
Precision-Recall (AUPR) and Receiver Operating Characteristic
(AUROC) curves, and ranked using the mean rank of these two
measures. The predictions for the continuous outcome (symptom
severity) were assessed using Pearson’s correlation (r) with the
observed values. In each case, permutation-based p values were
used to identify submissions that performed signiﬁcantly better
than those expected at random. In total, 37 teams participated in
some stage of the challenge (Supplementary Table 1).
Challenge results. For presence of symptoms (SC2), 27 models
were assessed on the independent test data; 13 models were
developed using T0 predictors, and 14 models using T24 predictors.
Four of the T0 models and three of the T24 models achieved a
nominal p value of 0.05 for AUPR or AUROC, with the best scoring
models at each timepoint achieving similar scores (AUPR(T0)=
0.958, AUROC(T0)= 0.863, AUPR(T24)= 0.953, AUROC(T24)=
0.863). Team Schrodinger’s Cat was the only team that achieved
nominal signiﬁcance for all measures and timepoints. Despite the
few teams achieving statistical signiﬁcance, the models submitted
were overall more predictive than expected at random (one-sided
Kolmogorov–Smirnov test for enrichment p values 0.008, 0.002,
0.021, and 0.05 for AUPR(T0), AUROC(T0), AUPR(T24), and
AUROC(T24), respectively; Fig. 2a).
For symptom severity (SC3), 23 models were assessed on the
independent test data; 11 models were developed using T0
predictors and 12 models using T24 predictors. Four of the T0
models and two of the T24 models achieved a nominal p value of
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0.05 for correlation with the observed log-symptom score, and as
above, the best performing models scored similarly at both
timepoints (r= 0.490 and 0.495 for T0 and T24, respectively).
Teams cwruPatho and Schrodinger’s Cat achieved signiﬁcant
scores at both timepoints. Consistent with SC2, we also saw that
the models submitted were overall more predictive than expected
at random (one-sided Kolmogorov–Smirnov test for enrichment
p values 0.005 and 0.035 for T0 and T24, respectively; Fig. 2b). For
both SC2 and SC3, enrichment was more pronounced at T0
compared to T24. Correlation between ﬁnal scores and leader-
board scores was higher at T0, suggesting T24 predictions may
have been subject to a greater degree of overﬁtting.
For viral shedding (SC1), 30 models were assessed from 16
different teams; 15 models were developed using T0 predictors and
15 models using T24 predictors. No submissions were statistically
better than expected by random. In aggregate, these submissions
showed no enrichment (one-sided Kolmogorov–Smirnov test for
enrichment p values 0.94, 0.95, 0.82, and 0.95, for AUPR(T0),
AUROC(T0), AUPR(T24), and AUROC(T24), respectively). In
contrast, ﬁnal scores were negatively correlated with leaderboard
scores (r=−0.22, −0.19, −0.65, and −0.54 for AUPR(T0),
AUROC(T0), AUPR(T24), and AUROC(T24), respectively) suggest-
ing strong overﬁtting to the training data or a lack of
correspondence to viral shedding as assessed in the independent
test data set, relative to the training data sets. The negative
correlation was strongest at T24 (Supplementary Figure 2).
Accordingly, results based on this subchallenge were excluded
from further analysis.
Best performing approaches. The two overall best performing
teams were Schrodinger’s Cat and cwruPatho. Team Schrodinger’s
Cat used the provided gene expression proﬁles before the viral
exposure to predict shedding and log symptom scores (binary and
continuous outcomes, respectively). For the T0 models, arithmetic
means over measurements prior to exposure were calculated,
whereas for the T24 models, only the latest measurements before
viral exposure were used. Epsilon support vector regression (epsi-
lon-SVR)16 with a radial kernel and tenfold cross-validation were
used to develop the predictive models. Their work demonstrated
c
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Fig. 1 Respiratory Viral DREAM Challenge overview. a Schematic representation of the Respiratory Viral DREAM Challenge workﬂow. Participants used
feedback from evaluation on the leaderboard test set to optimize their T0 and T24 models, and submitted a single model, per timepoint, for ﬁnal evaluation
on the Independent Test Set. b Schematic representing the data provided to participants. 125 subjects were provided as training data, 23 subjects were
provided as a leaderboard test set, and 21 subjects from an independent data set were used for ﬁnal evaluation. c Challenge data come from seven viral
exposure trials with sham or one of four different respiratory viruses (H1N1, H3N2, Rhinovirus, and RSV). In each of these trials, healthy volunteers were
followed for 7−9 days following controlled nasal exposure to one respiratory virus. Blood was collected and gene expression of peripheral blood was
performed 1 day (24−30 h) prior to exposure, immediately prior to exposure and at regular intervals following exposure. Data were split into a training,
leaderboard, and independent test set. Outcome data for the leaderboard and independent test set were not provided to the teams, but instead, teams
were asked to predict them based on gene expression pre-exposure (T0) or up to 24 h post-exposure (T24). d Histograms and boxplot of the three
outcomes by viruses. Symptom data and nasal lavage samples were collected from each subject on a repeated basis over the course of 7−9 days. Viral
infection was quantiﬁed by measuring the release of viral particles from viral culture or by qRT-PCR (viral shedding). Symptomatic data were collected
through self-report on a repeated basis. Symptoms were quantiﬁed using a modiﬁed Jackson score, which assessed the severity of eight upper respiratory
symptoms (runny nose, cough, headache, malaise, myalgia, sneeze, sore throat, and stuffy nose). On the boxplot, the lower whisker, the lower hinge, the
mid hinge, the upper hinge and the upper whisker correspond to −1.5× the interquartile (IQR) from the ﬁrst quartile, the ﬁrst quartile, the median, the third
quartile and 1.5× IQR from the third quartile of the log symptom score, respectively
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that predictive models of symptoms following viral exposure can be
built using pre-exposure gene expression.
Team cwruPatho constructed models of infection based on
pathway modulation, rather than gene expression, to predict
infection outcomes. To do so, they used a sample-level
enrichment analysis (SLEA)17 approach to summarize the
expression of genes implicated in the Hallmark gene sets18 of
the Molecular Signature DataBase (MSigDB)19. They then ﬁtted
LASSO regularized regression models, which integrate feature
selection with a regression ﬁt20, on the pathways to predict
shedding, presence of symptoms and symptom severity following
viral exposure. Their work demonstrated that including multiple
genes sharing the same biological function results in more robust
prediction than using any single surrogate gene.
Teams Schrodinger’s Cat and cwruPatho used different feature
transformation methods and machine learning approaches, suggest-
ing that multiple approaches can successfully identify pre- or early
post-exposure transcriptomic markers of viral infection suscept-
ibility or resilience. To gauge the range of approaches taken, we
extended this comparison to all Respiratory Viral DREAM
Challenge teams who reported details on the methods they used
to develop their submissions. We assessed the range of data
preprocessing, feature selection, and predictive modeling
approaches employed for the submissions, to determine whether
any of these methods were associated with better prediction
accuracy. Details of these three analysis steps (preprocessing, feature
selection and predictive modeling) were manually extracted from
reports of 24 teams (35 separate reports) who submitted predictions
either for the leaderboard test set or the independent test set. To
more precisely reﬂect the conceptual variations across employed
methodologies, each of these three analysis tasks was broken down
into four data preprocessing categories, seven feature selection
categories and nine predictive modeling categories (Supplementary
Table 2). Twenty of 24 (83.3%) teams employed some version of
data preprocessing, the task most signiﬁcantly associated with
predictive ability (Supplementary Figure 3A). Speciﬁcally, exclusion
of sham-exposed subjects and data normalization associated best
with predictive performance (Fig. 3).
Feature selection and predictive modeling approaches posi-
tively associated with predictive ability differed depending on
whether the task was classiﬁcation (presence of symptoms) or
regression (symptom severity). Random forest-based predictive
models performed slightly better than support vector machine
(SVM)/support vector regression (SVR) methods at predicting
symptom status (SC2) (Supplementary Figure 3B). However,
there was no discernible pattern relating feature selection and
improved performance in SC2. Feature selection using machine
learning approaches such as cross-validation was associated with
improved performance in predicting symptom severity (SC3)
(Fig. 3), as were SVM/SVR approaches when compared to linear
regression model-based methods (e.g. logistic regression; Supple-
mentary Figure 3C). Of note, SVM/SVR approaches were the
most popular among the submissions.
We also sought to compare cross-timepoint predictions to
determine the stability of predictions by timepoint. Signiﬁcant
correlation was observed between predictions using T0 and T24
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Fig. 2 Models perform better than expected at random. Observed −log10(p value) versus the null expectation for submitted predictions for predicting a
presence of symptoms (SC2) and b log symptom score (SC3), where p values were assessed by permutation of the predictions relative to the true values.
For both subchallenges signiﬁcant enrichment of p values (Kolmogorov–Smirnov test for enrichment p value 0.008, 0.002, 0.021, and 0.05 for AUPR(T0),
AUROC(T0), AUPR(T24), and AUROC(T24), respectively, for presence of symptoms, and one-sided Kolmogorov–Smirnov test for enrichment p value
0.005 and 0.035 for T0 and T24, respectively, for log symptom score) across submissions demonstrates that pre-exposure and early post-exposure
transcriptomic data can predict susceptibility to respiratory viruses
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gene expression for symptomatic classiﬁcation (SC2) (Leader-
board: ρ= 0.608, p value= 1.04e-61; Independent test set: ρ=
0.451, p value= 2.05e-25). Interestingly, we observed that
approximately 25% of subjects were difﬁcult to predict based
on T0 gene expression proﬁle (inherently difﬁcult; Supplementary
Figure 4); similarly, approximately 25% of subjects were correctly
predicted by the majority of teams (inherently easy; Supplemen-
tary Figure 4). Inherently difﬁcult subjects were also misclassiﬁed
when T24 gene expression data was used for prediction.
Inherently easy subjects were also consistently easy to classify
using T24 gene expression data. This suggests ab initio
characteristics allow some subjects to be more susceptible or
resilient to symptomatic disease and that, within 24 h, those
characteristics are not substantially altered in post-exposure
peripheral blood expression proﬁles.
Biological interpretation of predictors. In addition to predic-
tions, each team was asked to submit lists of gene expression fea-
tures used in their predictive models. Twenty-four teams submitted
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Fig. 3 Preprocessing leads to more accurate predictions. a Schematic representation of the analysis of the participating teams’ writeups to identify
methodological steps associated with more accurate prediction of symptoms. First, the writeups were manually inspected to identify the preprocessing, feature
selection and predictive modeling method used by each team. Second, the methods were regrouped into general categories across teams. Third, each general
method was assessed for its association with predictive model accuracies on the leaderboard test set and the independent test set. On the boxplot, the lower
whisker, the lower hinge, the mid hinge, the upper hinge and the upper whisker correspond to−1.5× IQR from the ﬁrst quartile, the ﬁrst quartile, the median, the
third quartile and 1.5× IQR from the third quartile of the AUROC, respectively. b Heatmap showing the association of each general method with prediction ability
(i.e. AUROC for SC2 (prediction of symptom presence) and Pearson’s correlation coefﬁcient for SC3 (prediction of symptom severity)). For each general
method, a Wilcoxon rank-sum test was used to assess the association between using the method (coded as a binary variable) and prediction ability
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predictive models with AUROC > 0.5 for SC2 or r > 0 for SC3
(leaderboard test set) for either T0 or T24, among which six teams
submitted separate models for each virus and reported virus-speciﬁc
predictors. The remaining 18 reported models independent of virus,
submitting a single model for all viruses. With the exception of the
list from cwruPatho, which used pathway information in the
selection of features, pathway analysis of individual predictor lists
showed no enrichment of pathways from MSigDB19, possibly due
to the tendency of most feature selection algorithms to choose one
or few features from within correlated sets.
We then assessed whether models showing predictive ability
(leaderboard test set AUROC > 0.5 for SC2 or r > 0 for SC3)
tended to pick the same gene features, or whether the different
gene sets may provide complementary information. Within each
subchallenge and timepoint, the signiﬁcance of the overlap
among predictor lists was calculated for every combination of two
or more predictor lists across teams. All two-way, three-way,
four-way, etc. overlaps were considered. This analysis revealed
that there were no genes shared among all teams for any
timepoint or subchallenge (Fig. 4a).
Despite the paucity of overlap among predictor lists, we sought
to identify whether genes used in the predictive models were part
of the same biological processes or pathways. In other words, we
examined whether different teams might have chosen different
surrogate genes to represent the same pathway. To test this
hypothesis, we performed pathway enrichment analysis of the
union of predictors across predictor lists within timepoint and
subchallenge. We observed signiﬁcant enrichments in each case
(Fig. 4b), suggesting that predictive gene features are indeed
complementary across models. More pathways were enriched
among predictors from T24 models (SC2= 17 pathways and SC3
= 20 pathways) than from T0 models (SC2= 15 pathways and
SC3= 17 pathways). At T0, genes involved in the metabolism of
heme and erythroblast differentiation (heme metabolism), genes
speciﬁcally upregulated by KRAS activation (KRAS signaling
(up)), genes deﬁning an inﬂammatory response (inﬂammatory
response) and genes mediating cell death by activation of caspases
(apoptosis) were associated with presence of symptoms in both
SC2 and SC3 (Fig. 4b). At T24, along with heme metabolism, the
expression of several inﬂammatory response pathways like KRAS
signaling, inﬂammatory response, genes upregulated in response
to the gamma cytokine IFNg (interferon gamma response), genes
upregulated by IL6 via STAT3 (IL6 JAK STAT3 signaling), genes
regulated by NF-κB in response to TNF (TNFA signaling via
NFKB) and genes encoding components of the complement
system (complement) were associated with symptoms in both
SC2 and SC3 (Fig. 4b). Additionally, there was a signiﬁcant
overlap in genes across timepoints and subchallenges in each of
these enriched pathways (Fisher’s exact test p value ≤ 0.05)
(Supplementary Data 2).
A meta-analysis across subchallenges (SC2 and SC3) and
timepoints (T0 and T24) was performed in order to identify the
most signiﬁcant pathways associated with outcome. Heme
metabolism was the most signiﬁcantly associated with developing
symptoms (susceptibility), while oxidative phosphorylation and
MYC targets were the most signiﬁcantly associated with a lack of
symptoms (resilience) (Supplementary Figure 5). This indicates that
heme, known to generate inﬂammatory mediators through the
activation of selective inﬂammatory pathways21 is the best predictor
of becoming symptomatic both pre- and early post-exposure to
respiratory viruses. Genes in heme metabolism associated with
symptoms include genes coding for the hemoglobin subunits (HBB,
HBD, HBQ1, and HBZ), the heme binding protein (HEBP1) and
genes coding for enzymes important for the synthesis of heme
(ALAS2, FECH, HMBS, UROD). It also includes glycophorins,
which are the major erythrocyte membrane proteins (GYPA, GYPB,
GYPC, and GYPE), which are known receptors for the inﬂuenza
virus (Fig. 4c)22,23. Genes essential for erythroid maturation and
differentiation (NEF2, TAL1, EPOR, and GATA1), including the
transcription factor GATA1 and its targets, the hemoglobin subunit
genes HBB and HBG1/2, were also part of heme metabolism
associated with an increase in symptom frequency and severity.
Discussion
Using an open data analysis challenge framework, this study
showed that models based on transcriptomic proﬁles, even prior to
viral exposure, were predictive of infectious symptoms and symp-
tom severity, which has not been previously demonstrated. The best
scoring individual models for predicting symptoms and log-
symptom score, though statistically signiﬁcant, fall short of prac-
tical signiﬁcance. However, these outcomes suggest that there is
potential to develop models and ultimately, clinically relevant tests,
based on the knowledge gained from these results. This would
necessitate further efforts to generate more data or identify different
biomarker assays which more accurately assess the mechanisms
observed in the transcriptomic models. Additionally, since these
studies focused on healthy adults, further data generation should
extend to a wider range of subjects with respect to age and health
status, as well as tracking and modeling these cofactors.
A generally useful exercise in crowdsourcing-based challenges is
to construct ensembles from the submissions to assimilate the
knowledge contained in them, and boost the overall predictive
power of the challenge24. This exercise has yielded useful results in
earlier benchmark studies25,26 and the DREAM Rheumatoid
Arthritis Challenge27. However, the ensembles constructed for the
Respiratory Viral DREAM Challenge did not perform better than
the respective best performers among all the individual submissions
for the various subchallenges and timepoints. We attribute this
shortcoming partly to the relatively small training set (118 subjects),
which may incline the ensemble methods to overﬁt these data, and
the assumption of class-conditioned independence of the submis-
sions inherent in SUMMA may not have been appropriate in this
challenge28. The relative homogeneity, or lack of diversity, among
the submissions for the various subchallenges and timepoints may
have been another potential factor behind the diminished perfor-
mance of the ensembles29.
The relative homogeneity of submissions and observation that
the same subjects are misclassiﬁed by almost all participating teams
suggests there may be a plateau in predictive ability when using
gene expression to predict the presence of symptoms or symptom
severity. It is possible that an integrative analysis supplementing or
replacing the gene expression data with post-transcriptional (such
as metabolomic or proteomic) data could further improve accuracy.
For example, metabolomic data have been used to differentiate
patients with inﬂuenza H1N1 from others with bacterial pneumo-
nia or non-infectious conditions as well as differentiate inﬂuenza
survivors from nonsurvivors30. With respect to proteomics, Burke
et al. used four of the viral exposure studies described here to derive
and validate a proteomic signature from nasal lavage samples which
distinguish, with high accuracy, symptomatic from asymptomatic
subjects at the time of maximal symptoms31. Several cytokines have
been investigated in a variety of infectious disease conditions. Of
particular relevance, cytokine proﬁling has been performed for one
of the inﬂuenza H3N2 studies used in this Challenge. In that work,
McClain et al. demonstrated that several cytokines were upregulated
early after viral exposure (within 24 h in some cases) and differ-
entiated symptomatic from asymptomatic cases32. Baseline differ-
ences in cytokine expression were not observed, however,
suggesting that cytokine expression is useful for predicting response
to viral exposure but not baseline susceptibility. To our knowledge,
no study has identiﬁed baseline metabolomic or proteomic
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predictors of resilience or susceptibility to respiratory viral infection.
In addition, the combination of these data with transcriptomic
predictors has not yet been investigated and may yield robust
predictors of susceptibility or resistance to infection.
Our analyses revealed a signiﬁcant concordance between pre-
dictions at T0 and T24 (Supplementary Figure 4), as well as a
signiﬁcant overlap between predictors at each of these timepoints
(Supplementary Data 2). Given the stability of predictions and
predictors between T0 and T24, it appears that the pre-exposure
biological mechanisms conferring susceptibility or resilience to
respiratory viral infection may be observable up to 1 day post-
exposure. We also observed signiﬁcant overlap between gene
signatures at both T0 and T24 and late stage signatures of viral
infection, reported in the literature, and derived from gene
expression 48 h or later after viral exposure (Supplementary
Data 3)5–9,15,33–38. The overlap between the predictors identiﬁed
in this study and the later stage signatures was more signiﬁcant at
T24 than T0, suggesting that pre-exposure signatures of suscept-
ibility differ somewhat from post-exposure signatures of active
infection, and T24 predictors may reﬂect some aspects of both.
The T0 gene signatures may encompass novel insight into ab
initio factors that confer resilience or susceptibility.
Pathway enrichment analysis in our study revealed that the most
signiﬁcantly enriched pathway associated with symptomatic infec-
tion was heme metabolism, known to have a direct role in
immunity through activation of innate immune receptors on
macrophages and neutrophils21. Of note, genes part of heme
metabolism were also enriched among late stage signatures of viral
infection (ex. Hemoglobin gene HBZ and the iron containing gly-
coprotein ACP5 in ref.33). Iron (obtained from heme) homeostasis
is an important aspect of human health and disease. Viruses require
an iron-rich host to survive and grow, and iron accumulation in
macrophages has been shown to favor replication and colonization
of several viruses (e.g. HIV-1, HCV) and other pathogenic micro-
organisms39. Furthermore, iron-replete cells have been shown to be
better hosts for viral proliferation39. Increased iron loading in
macrophages positively correlates with mortality39 and it has been
shown that viral infection can cause iron overload which could
further exacerbate disease. Additionally, previous evidence suggests
counteracting iron accumulation may limit infection21,39. Studies
have shown that limiting iron availability to infected cells (by the
use of iron chelators) curbed the growth of several infectious viruses
and ameliorated disease21,39–41. This important role of iron in the
susceptibility and response to infection may be the mechanism by
which heme metabolism genes conferred susceptibility to respira-
tory viral infection. As such, it represents an important
biological pathway potentially offering a means by which an indi-
vidual’s susceptibility or response to infection can be optimized.
Such a relationship should be investigated in future studies of
infection susceptibility. In addition, Heme-oxygenase (HMOX1), a
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heme-degrading enzyme that antagonizes heme-induced inﬂam-
mation and is essential for the clearance of heme from circulation42,
was among the predictors from the T0 models. Interestingly, the
expression of this gene at baseline was associated with a lack of
symptoms (for both SC2 and SC3), in concordance with its
reported antiviral role during inﬂuenza infection43,44. Augmenta-
tion of HMOX1 expression by gene transfer had provided cellular
resistance against heme toxicity45. Hence enhancing HMOX1
activity could be an alternative to antagonize heme-induced effects
and thereby controlling infection and inﬂammation.
In addition to heme metabolism, pro-inﬂammatory pathways
such as inﬂammatory response, KRAS signaling, and apoptosis
were also associated with susceptibility to viral infection in our
study, while homeostatic pathways, such as oxidative phosphor-
ylation and MYC targets, were associated with resilience, both
prior to and post viral exposure (Fig. 4). Enrichment of these
pathways among T24 predictors was more signiﬁcant than among
the T0 predictors, suggesting these mechanisms are not only
emblematic of baseline system health, but also response to viral
invasion. Additional pathways enriched among T24 predictors
include interferon gamma response and complement, which are
involved in innate and acquired immunity. Several genes among
T0 and T24 predictors overlapped with genes positively associated
with ﬂu vaccination response46. Among them, FCER1G and
STAB1, members of the inﬂammatory response pathway posi-
tively associated with symptoms in this study and were elevated
prior to vaccination in young adults who showed good response
to vaccination46 (Fisher exact test: p= 0.0338 for T0 and p=
0.000673 for T24). This suggests that individuals predicted at a
higher risk of presenting symptoms following inﬂuenza exposure
may also be the most likely to beneﬁt from vaccination.
The Respiratory Viral DREAM Challenge is to date the largest
and most comprehensive analysis of early stage prediction of viral
susceptibility. The open data analysis challenge framework is useful
for comparing approaches and identifying the most scientiﬁcally or
clinically relevant model or method in an unbiased fashion24. In
this case, we observed few commonalities among the best per-
forming models of symptomatic susceptibility to respiratory viral
exposure. Indeed, the overall best performing teams in the challenge
used different machine learning techniques to build their models.
Interestingly, data preprocessing was the analysis task most sig-
niﬁcantly associated with model accuracy, suggesting what has often
been speculated, that adequate attention to data processing prior to
predictive modeling is a crucial ﬁrst step47.
The open data challenge framework is also useful in arriving at
consensus regarding research outcomes that may guide future
efforts within a ﬁeld24. Through this challenge, we have identiﬁed
ab initio transcriptomic signatures predictive of response to viral
exposure, which has provided valuable insight into the biological
mechanisms conferring susceptibility to infection. This insight
was not evident from any individual model, but became apparent
with the meta-analysis of the individual signatures. While
development of a diagnostic test of baseline susceptibility is not
yet feasible based on these ﬁndings, they suggest potential for
development in this area.
Methods
Training data. Training data came from seven related viral exposure trials,
representing four different respiratory viruses. The data sets are DEE1 RSV, DEE2
H3N2, DEE3 H1N1, DEE4X H1N1, DEE5 H3N2, Rhinovirus Duke, and Rhino-
virus UVA6,7,9. In each of these human viral exposure trials, healthy volunteers
were followed for 7−9 days following controlled nasal exposure to the speciﬁed
respiratory virus. Subjects enrolled into these viral exposure experiments had to
meet several inclusion and exclusion criteria. Among them was an evaluation of
pre-existing neutralizing antibodies to the viral strain. In the case of inﬂuenza
H3N2 and inﬂuenza H1N1, all subjects were screened for such antibodies. Any
subject with pre-existing antibodies to the viral strain was excluded. For the
rhinovirus studies, subjects with a serum neutralizing antibody titer to RV39 > 1:4
at prescreening were excluded. For the RSV study, subjects were prescreened for
neutralizing antibodies, although the presence of such antibodies was not an
exclusion criterion.
Symptom data and nasal lavage samples were collected from each subject on a
repeated basis over the course of 7−9 days. Viral infection was quantiﬁed by
measuring release of viral particles from nasal passages (viral shedding), as assessed
from nasal lavage samples via qualitative viral culture and/or quantitative inﬂuenza
RT-PCR. Symptom data were collected through self-report on a repeated basis.
Symptoms were quantiﬁed using a modiﬁed Jackson score14, which assessed the
severity of eight upper respiratory symptoms (runny nose, cough, headache,
malaise, myalgia, sneeze, sore throat, and stuffy nose) rated 0−4, with 4 being most
severe. Scores were integrated daily over 5-day windows.
Blood was collected and gene expression of peripheral blood was performed
1 day (24−30 h) prior to exposure, immediately prior to exposure, and at regular
intervals following exposure. These peripheral blood samples were gene expression
proﬁled on the Affy Human Genome U133A 2.0 array.
All subjects exposed to inﬂuenza (H1N1 or H3N2) received oseltamivir 5 days
post-exposure. However, 14 (of 21) subjects in the DEE5 H3N2 cohort received
early treatment (24 h post-exposure) regardless of symptoms or shedding.
Rhinovirus Duke additionally included seven volunteers who were exposed to sham
rather than active virus.
All subjects provided written consents, and each of the seven trials was reviewed
and approved by the appropriate governing IRB.
RSV test data. Healthy nonsmoking adults aged 18−45 were eligible for inclusion
after screening to exclude underlying immunodeﬁciencies. A total of 21 subjects
(10 female) were inoculated with 104 plaque-forming units of RSV A Memphis 37
(RSV M37) by intranasal drops and quarantined from 1 day before inoculation to
the 12th day after. Peripheral blood samples were taken immediately before
inoculation and regularly for the next 7 days and proﬁled on the Affy Human
Genome U133A 2.0 array. Subjects were discharged after study day 12, provided no
or mild respiratory symptoms and a negative RSV antigen respiratory secretions
test. Shedding was determined by polymerase chain reaction (PCR) in nasal lavage
and deﬁned as detectable virus for ≥2 days between day +2 and day +10 to avoid
false-positives from the viral inoculum and to align case deﬁnitions with the other
seven studies. Subjects ﬁlled a diary of upper respiratory tract symptoms from day
−1 to day +12, which was summarized using a modiﬁed Jackson score. All subjects
returned for further nasal and blood sampling on day +28 for safety purposes. All
subjects provided written informed consent and the study was approved by the UK
National Research Ethics Service (London-Fulham Research Ethics Committee ref.
11/LO/1826).
Gene expression normalization. Both raw (CEL ﬁles) and normalized versions of
the gene expression data were made available to teams in the Challenge. Both
versions contained only proﬁles that pass QC metrics including those for RNA
Degradation, scale factors, percent genes present, β-actin 3′ to 5′ ratio and GAPDH
3′ to 5′ ratio in the Affy Bioconductor package. Normalization via RMA was
performed on all expression data across all timepoints for the training and lea-
derboard data sets. The RSV data were later normalized together with the training
and leaderboard data, and teams were free to further QC and normalize the data in
the way they deemed appropriate.
Analysis challenge design. The training data studies were split into training and
leaderboard sets, where the leaderboard subjects were chosen randomly from three
of the trials: DEE4X H1N1, DEE5 H3N2, and Rhinovirus Duke, which were not
publicly available at the time of challenge launch. Outcome data for the leader-
board set were not provided to the teams, but instead, teams were able to test
predictions in these individuals using the leaderboard, with a maximum of six
submissions per subchallenge, the purpose of which was to allow teams to optimize
their models prior to assessment on the independent test data. Of these, at least one
submission was required to use only data prior to viral exposure and at least one
using data up to 24 h post-exposure.
For the training data, teams had access to clinical and demographic variables:
age, sex, whether the subject received early oseltamivir treatment (DEE5 H3N2
only) and whether the subject received sham exposure rather than virus
(Rhinovirus Duke only), as well as gene expression data for the entire time-course
of the studies. They also received data for the three outcomes used in the data
analysis challenge:
● Subchallenge 1: SHEDDING_SC1, a binary variable indicating the presence of
virus in nasal swab following exposure;
● Subchallenge 2: SYMPTOMATIC_SC2, a binary variable indicating post-
exposure maximum 5-day integrated symptom score ≥6;
● Subchallenge 3: LOGSYMPTSCORE_SC3, a continuous variable indicating
the log of the maximum 5-day integrated symptom score +1
as well as the granular symptom data by day and symptom category. For the
leaderboard test data, they were supplied with the clinical and demographic
variables and gene expression data up to 24 h post-exposure.
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Final assessment of optimized models was performed in the RSV Test Data (i.e.
the independent test set), and outcomes for these subjects were withheld from
teams. In order to assure that predictions were limited to data from the appropriate
time window, the gene expression data were released in two phases corresponding
to data prior to viral exposure, and data up to 24 h post exposure. Teams were also
supplied with age and sex information for these subjects.
The Challenge was launched and training data were released on May 15, 2016
for participants to use to begin analyzing the data and building their models. In
total 38 teams registered for the challenge and 37 participated (Supplementary
Table 1). The leaderboards opened approximately 2 months later, and were open
for approximately 3 months (July to September) to allow participants to optimize
their models with feedback from the scores on the leaderboard data. At the close of
this round on September 30, participating teams were also required to submit code,
methodological writeups, predictor lists, and LOOCVs, and doing so qualiﬁed
participants to be included as authors (either Consortium or by-line) on this
manuscript. Participating teams could opt to evaluate their optimized models in the
independent test data, which occurred from January to February 2017. At the close
of the challenge, participating teams were invited to collaborate with the Challenge
Organizers to analyze the results. Prior to the launch of the challenge, substantial
effort was put forth by the Challenge organizers to collate and vet the data, to
determine the feasibility of the Challenge and deﬁne the Challenge objectives. For
further details on the organizational efforts required to prepare for a challenge, see
Saez-Rodriguez et al.24.
Submission scoring. Team predictions were compared to true values using AUPR
and AUROC for subchallenges 1 and 2, and Pearson correlation for subchallenge 3.
For each submission, a p value, estimating the probability of observing the score
under the null hypothesis that the predicted labels are random, was computed by
10,000 permutations of the predictions relative to the true values.
Enrichment of p values of the submitted models was assessed via 1-sided
Kolmogorov–Smirnov test with a null hypothesis that the p values follow a U[0,1]
distribution, and an alternative hypothesis that they follow a distribution that is
stochastically smaller than U[0,1].
Heterogeneity of the predictions. T0 and T24 predictions for each outcome and
team were collected to assess whether they were correlated. Three teams provided
predictions as binary values while 12 teams provided predictions as continuous
values on different scales. In order to compare binary and continuous predictions,
we ﬁrst transformed them into ranks (with ties given the same average rank) and
then ordered subjects increasingly by their mean rank across outcomes (mean-
rank). The lower the mean-rank, the more likely a subject was predicted by the
teams as not showing symptoms, whereas a higher mean-rank means a subject was
predicted by most of the teams as showing symptoms. Distribution of the mean-
rank (Supplementary Figure 4) revealed three groups of subjects: (1) ~25% of
subjects correctly predicted by most of the teams (i.e. inherently easy), (2) ~25% of
subjects incorrectly predicted by most of the teams (i.e. inherently difﬁcult) and (3)
~50% of subjects who were predicted differently by the teams.
Ensemble prediction. We constructed a variety of ensembles from the teams’
submissions to the various subchallenges as a part of the collaborative phase of the
Respiratory Viral DREAM Challenge. To enable a comparative analysis between
individual and ensemble models in the collaborative phase, the teams were
requested to submit LOOCV-derived predictions on the training examples using
the same methods used to generate leaderboard and/or test set predictions in the
competitive phase. The LOOCV setup, which does not involve random subsetting
of the training data, was chosen to avoid potential overﬁtting that can otherwise
occur from training and testing on predictions made on the same set of examples25.
We used three types of approaches for learning ensembles, namely stacking and its
clustering-based variants25, Reinforcement Learning-based ensemble selection26
methods, as well as SUMMA, an unsupervised method for the aggregation of
predictions28. Consistent with the process followed by the individual teams, we
learned all the ensembles using the training set LOOCV-derived predictions
described above, and used the leaderboard data to select the ﬁnal models to be
evaluated on the test data.
Combined gene sets. Statistical signiﬁcance of the overlap among predictor lists
was calculated using the multiset intersection probability method implemented in
the SuperExactTest R package48. A ﬁrst set of analysis was performed with teams
whose leaderboard AUROC > 0.5. A second set of analysis aimed at identifying
genes that overlap virus-speciﬁc, subchallenge-speciﬁc and timepoint-speciﬁc
predictive models, was restricted to teams that provided virus-speciﬁc (Nautilus,
aydin, SSN_Dream_Team, Txsolo, cwruPatho and Aganita), subchallenge-speciﬁc
(aydin, SSN_Dream_Team, cwruPatho, jhou) and timepoint-speciﬁc predictors
(aydin, SSN_Dream_Team, cwruPatho, Espoir, jdn, jhou, burkhajo) and partici-
pated in the leaderboard phase of the challenge, respectively. For both analyses,
overlapping predictors associated with p values less than or equal to 0.005 were
considered signiﬁcant49.
Pathway enrichment analysis. To assess pathway enrichment among predictors
of infection, we considered predictors from teams with leaderboard AUROC > 0.5
(SC2) or Pearson correlation, r > 0 (SC3). Affymetrix Human U133A 2.0 GeneChip
probe identiﬁers were mapped to gene symbols. We removed probes matching
multiple genes, and when multiple probes matched a single gene, we retained the
probe with the maximum median intensity across subjects.
For the list of predictors of presence of symptoms (SC2), we calculated the log2
fold-change of features (symptomatic(1)/asymptomatic(0)) at T0 and T24, and for
prediction of the symptom scores (SC3), we calculated the Spearman’s correlation
coefﬁcient of the features, at T0 and T24, with the outcome. Pathway enrichment
was then performed on the union of all predictors (across the teams) that were
associated with presence/increase severity of symptoms (SC2: log2 fold-change > 0
and SC3: Spearman’s correlation > 0), as well as, for the union of all predictors
(across teams) that were associated with lack of symptoms/lower symptoms
severity (SC2: log2 fold-change < 0 and SC3: Spearman’s correlation < 0), separately
by timepoint and subchallenge. We used the Hallmark gene sets (version 6.0)18 of
the Molecular Signature DataBase (MSigDB)19 for the enrichment analysis, and
calculated the signiﬁcance using Fisher’s exact test. The resulting p values were
corrected for multiple comparisons using the Benjamini and Hochberg algorithm.
Only signiﬁcantly enriched pathways (corrected p value < 0.05) were reported.
Meta-analyses across subchallenges and timepoints were performed using the
maxP test statistic50.
Code availability. Code for individual models are available through www.synapse.
org/ViralChallenge.
Data availability
Data are available through GEO GSE73072. Challenge results and methods and
code for individual models are available through www.synapse.org/ViralChallenge.
The authors declare that all other data supporting the ﬁndings of this study are
available within the article and its Supplementary Information ﬁles, or are available
from the authors upon request.
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